# US 2010/0166800 A1 · Recombinant attenuated clostridium organisms and vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166800 A1
- Document ID: US20100166800A1
- Status: Published application
- Kind: A1
- Application number: 12/640,645
- Filed: 2009-12-17
- Published: 2010-07-01
- Earliest claimed: 2006-04-17
- Assignees: Intervet Inc.
- Inventors: Mark D. Cochran; Gary R. Petersen; Stephen V. Lair; Richard M. Synenki
- Web page: https://patentgrep.com/patent/US20100166800A1

## CPC

- A61K 39/08: Clostridium, e.g. Clostridium tetani
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- C07K 14/33: from Clostridium (G)
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/523: {expressing foreign proteins}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.

## Claims

### Claim 1

A nucleic acid molecule that encodes a substantially nontoxic mutein of Clostridium perfringens alpha-toxin; wherein the mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 minus at least 9 consecutive amino acid residues; and wherein one of the deleted amino acid residues is His68.

### Claim 2 (depends on 1)

The nucleic acid molecule of claim 1 wherein the mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 minus at least 12 consecutive amino acid residues; and wherein one of the deleted amino acid residues is His68.

### Claim 3 (depends on 2)

The nucleic acid molecule of claim 2 wherein the mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 minus at least 18 consecutive amino acid residues; and wherein one of the deleted amino acid residues is His68.

### Claim 4 (depends on 1)

The nucleic acid molecule of claim 1 wherein the mutein alpha-toxin comprises SEQ ID NO: 3 minus 9 consecutive amino acid residues ranging from Tyr62 through Trp70.

### Claim 5 (depends on 1)

The nucleic acid molecule of claim 1 comprising the nucleic acid sequence of SEQ ID NO: 2; wherein nucleotides 268-294 of the nucleic acid molecule are deleted.

### Claim 6 (depends on 5)

The nucleic acid molecule of claim 5 wherein the deleted nucleotides are replaced by a nucleotide sequence encoding a single Leu residue.

### Claim 7

A substantially nontoxic mutein of Clostridium perfringens alpha-toxin; wherein the mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 minus at least 9 consecutive amino acid residues; and wherein one of the deleted amino acid residues is His68.

### Claim 8 (depends on 7)

The substantially nontoxic mutein of Clostridium perfringens alpha-toxin of claim 7 wherein the mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO: 3 minus at least 12 consecutive amino acid residues; and wherein one of the deleted amino acid residues is His68.

### Claim 9 (depends on 8)

The substantially nontoxic mutein of Clostridium perfringens alpha-toxin of claim 8, wherein said mutein comprises the amino acid sequence of SEQ ID NO: 3 minus at least 18 consecutive amino acid residues; and wherein one of the deleted amino acid residues is His68.

### Claim 10 (depends on 7)

The substantially nontoxic mutein of Clostridium perfringens alpha-toxin of claim 7, wherein nine consecutive amino acid residues that range from Tyr62 through Trp70, are deleted and replaced by a single Leu residue.

### Claim 11 (depends on 1)

An attenuated Clostridium perfringens organism constructed by integrating the nucleic acid molecule of claim 1 into a chromosome of a non-attenuated Clostridium perfringens organism.

### Claim 12 (depends on 11)

The attenuated Clostridium perfringens organism of claim 11 that is substantially nontoxic.

### Claim 13 (depends on 11)

The attenuated Clostridium perfringens organism of claim 11 wherein the nucleic acid molecule is located at a position on the chromosome that is homologous to the location of a nucleic acid molecule encoding a wild-type alpha-toxin present in the non-attenuated Clostridium perfringens.

### Claim 14 (depends on 11)

The attenuated Clostridium perfringens organism of claim 11 that is a type A Clostridium perfringens.

### Claim 15 (depends on 11)

The attenuated Clostridium perfringens organism of claim 11 wherein the non-attenuated Clostridium perfringens from which it was constructed was isolated from a host animal that is either a mammal or an avian.

### Claim 16 (depends on 15)

The attenuated Clostridium perfringens organism of claim 15, wherein said mammal is selected from the group consisting of bovine, ovine, and porcine.

### Claim 17 (depends on 15)

The attenuated Clostridium perfringens organism of claim 15 wherein said avian is a chicken, a turkey, a goose, a duck, a swan, a dove, a pigeon, a grouse, or a partridge.

### Claim 18 (depends on 11)

A vaccine comprising the attenuated Clostridium perfringens organism of claim 11.

### Claim 19 (depends on 18)

The vaccine of claim 18 further comprising one or more of the following: a pharmacologically acceptable buffer, excipient, or an adjuvant.

### Claim 20 (depends on 18)

A method of inducing immunity to Clostridium perfringens in an animal, comprising administering to the animal an immunologically effective dose of the vaccine of claim 18.

### Claim 21 (depends on 20)

The method of claim 20 wherein the vaccine is administered by one or more of the following routes: oral, intramuscular, intravenous, intradermal, subcutaneous, or intranasal.

### Claim 22 (depends on 20)

The method of claim 20 wherein the vaccine is top-dressed on the feed of the animal.

### Claim 23 (depends on 20)

The method of claim 20 wherein the vaccine is sprayed onto the animals to provide for oral administration.

### Claim 24 (depends on 18)

An animal feed that comprises the vaccine of claim 18.

### Claim 25 (depends on 11)

The attenuated Clostridium perfringens organism of claim 11 that comprises at least one gene encoding a non-Clostridium perfringens polypeptide.

### Claim 26 (depends on 25)

The attenuated Clostridium perfringens organism of claim 25 wherein said non-Clostridium perfringens polypeptide is a non-bacterial polypeptide.

### Claim 27 (depends on 26)

The attenuated Clostridium perfringens organism of claim 26 wherein the non-bacterial polypeptide is an avian or mammalian polypeptide.

### Claim 28 (depends on 27)

The attenuated Clostridium perfringens organism of claim 27 wherein the non-bacterial polypeptide is an avian polypeptide.

### Claim 29 (depends on 27)

The attenuated Clostridium perfringens organism of claim 27 wherein the non-bacterial polypeptide is a cytokine.

### Claim 30 (depends on 29)

The attenuated Clostridium perfringens organism of claim 29 wherein the cytokine is chicken IL-18.

### Claim 31 (depends on 11)

An antibody that selectively binds to an epitope found in Clostridium perfringens alpha-toxin but missing from the substantially nontoxic mutein of Clostridium perfringens alpha-toxin of claim 11 wherein said antibody can distinguish said substantially nontoxic mutein from a wild type Clostridium perfringens alpha-toxin.

### Claim 32 (depends on 31)

A test kit for identifying whether a subject animal has been naturally infected by a Clostridium perfringens organism comprising the antibody of claim 31.

### Claim 33 (depends on 31)

A method of identifying an animal that has been naturally infected by a Clostridium perfringens organism from one vaccinated with an attenuated Clostridium perfringens organism, said method comprising:
(a) contacting a fluid sample from the animal with the antibody of claim 31,
(b) determining whether the antibody reacts with the fluid sample;
wherein when the antibody reacts with the fluid sample, the animal is identified as one that has been naturally infected by a Clostridium perfringens organism.

### Claim 34

A Clostridium perfringens organism that is CPERF/ΔαToxin 365-054 having ATCC Deposit No. PTA7364.

### Claim 35

A Clostridium perfringens organism that is CPERF/ΔαToxin 365-053 having ATCC Deposit No. PTA7365.
